
University of California,
San Diego (UCSD)
Rebecca and John Moores UCSD
Cancer Center
La Jolla, CA
The Burnham Institute
La Jolla, CA
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA
Long Island Jewish Medical
Center
Division of Hematology/Oncology
New Hyde Park, NY
M.D. Anderson Cancer Center
Houston, TX
Ohio State University
Cancer Center
Columbus, Ohio
Barts Cancer Centre of
Excellence
Barts Hospital
West Smithfield, London
Mayo Clinic
Rochester, MN

Kanti R. Rai, M.D.
Division of Hematology/Oncology
New Hyde Park, NY
(718) 470-7135
Long Island Jewish Medical Center
New patients should contact Susan Mrwik at (718) 470-7135 to request an appointment. Prior to your appointment, you will be contacted in order to review insurance coverage and to obtain additional information. Please have your insurance card and referral information available.
Kanti R. Rai, M.D.
Dr. Rai's major interest is in understanding the natural history of low-grade lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), and in devising improved therapies of hematological malignancies, especially CLL and acute myelocytic leukemia.
CLL is the most common adult leukemia in the western hemisphere. The disease predominantly affects the elderly population and is known to follow divergent clinical courses. Some patients survive especially long periods after diagnosis, whereas others die in a much shorter period of time. The clinical prognostic stratification of CLL, originally proposed by us and known as the Rai staging system, has provided a valuable clinical framework around which to classify patients and build therapeutic decisions. Moving beyond the clinical criteria and exploiting modern molecular biology techniques, Dr. Rai and his team of investigators are currently collaborating with Dr. Nicholas Chiorazzi to study the potential of immunoglobulin variable region gene mutation status and of CD38 expression as additional prognostic indicators.